CLINICAL STUDIES

PROMINENT

PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES

Study Phase:

Phase 3

Criteria:

  • Male or Female 18 years or older
  • Type 2 Diabetes Mellitus (T2DM)
  • Triglycerides ≥ 200 mg/dL (2.26 mmol/L)
Register